GeneDx Holdings (WGSWW) EBT (2020 - 2026)

GeneDx Holdings has disclosed EBT across 7 years of filings, most recently posting -$62.4 million for Q1 2026.

• In Q1 2026, EBT fell 926.29% year-over-year to -$62.4 million; the TTM figure through Mar 2026 stood at -$77.5 million (down 101.81% YoY), while the FY2025 annual figure was -$21.1 million, up 59.84% from the prior year.
• EBT retreated to -$62.4 million in Q1 2026, from -$18.2 million in the prior quarter.
• Over the last five years, EBT for WGSWW reached as high as $10.6 million in Q2 2025 and fell as low as -$308.7 million in Q4 2022.
• The 5-year median for EBT is -$29.4 million (2024), against an average of -$53.6 million.
• Annual changes were most pronounced in 2025 — EBT surged 135.97% — and 2026, when it slumped 926.29%.
• A 5-year view of EBT shows it stood at -$308.7 million in 2022, then surged by 91.52% to -$26.2 million in 2023, then surged by 120.68% to $5.4 million in 2024, then slumped by 436.72% to -$18.2 million in 2025, then slumped by 242.4% to -$62.4 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$62.4 million, -$18.2 million, and -$7.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.